ArticleESMO gastrointestinal oncology2026
Evaluating incidence and mortality trends of early-onset colorectal cancer and adenoma in Belgium.
Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Age Inflection Points of Colorectal Adenoma Risk in Young Adults: A Joinpoint Regression Analysis of a Single-Center Retrospective Colonoscopy-Based Cohort.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) incidence is rising among young adults globally, yet European data remain inconclusive. This study evaluated age- and sex-specific trends in CRC incidence, adenoma detection, and mortality in Belgium, with a focus on individuals aged 20-49 years. Diagnostic procedure trends in the 40-49 years age group were also analyzed to contextualize epidemiological patterns. Materials and methods: Data from the Belgian Cancer Registry and diagnostic records from health insurance organizations were used to analyze trends in invasive CRC, Results: Invasive CRC incidence remained stable in individuals aged 40-49 years between 2004 and 2023, whereas adenoma and Conclusions: Enhanced diagnostic activity in individuals aged 40-49 years appears to have led to earlier detection rather than increased advanced disease. These observations do not provide evidence that would support lowering the current starting age of organized screening. Rising CRC incidence in individuals aged 30-39 years warrants increasing clinical vigilance in younger adults with symptoms or elevated risk and requires further investigation into underlying drivers. Epidemiologic surveillance should preferably include precursor lesions and diagnostic activity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.